Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) Senior Officer Dennis Bourgeault sold 3,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of C$27.62, for a total transaction of C$82,860.00. Following the transaction, the insider now directly owns 70,891 shares of the company’s stock, valued at approximately C$1,958,009.42.
Dennis Bourgeault also recently made the following trade(s):
- On Monday, December 16th, Dennis Bourgeault sold 5,000 shares of Aurinia Pharmaceuticals stock. The stock was sold at an average price of C$24.08, for a total transaction of C$120,400.00.
- On Thursday, December 12th, Dennis Bourgeault sold 5,000 shares of Aurinia Pharmaceuticals stock. The stock was sold at an average price of C$24.55, for a total transaction of C$122,750.00.
Shares of AUP stock opened at C$27.76 on Wednesday. Aurinia Pharmaceuticals Inc has a 1-year low of C$4.70 and a 1-year high of C$28.59. The company has a current ratio of 10.26, a quick ratio of 9.99 and a debt-to-equity ratio of 0.31. The stock has a market cap of $2.92 billion and a price-to-earnings ratio of -40.29. The stock has a 50-day moving average of C$20.14 and a 200-day moving average of C$10.70.
Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last posted its quarterly earnings data on Thursday, November 14th. The company reported C($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of C($0.26) by C($0.01). The company had revenue of C$0.30 million during the quarter, compared to the consensus estimate of C$0.06 million. Sell-side analysts forecast that Aurinia Pharmaceuticals Inc will post -0.8199999 earnings per share for the current year.
A number of research firms recently weighed in on AUP. Bloom Burton restated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, October 17th.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Read More: How prevalent are 12b-1 fees?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.